Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
November 07 2017 - 6:00AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of effective immunotherapies for cancer and stem cell
therapies for degenerative diseases, held a Grand Opening ceremony
on November 4, 2017 for its new Shanghai facility located in
“Pharma Valley” in Shanghai Zhangjiang High-Tech Park. Local
dignitaries, partners and collaborating medical institutions were
present for the ribbon cutting ceremony and the launch of the
“CBMG-GE Joint Laboratory of Cell Therapy”.
Photos accompanying this announcement are available
at
http://www.globenewswire.com/NewsRoom/AttachmentNg/9c4e9dcf-257d-4781-9f87-44683089487f
http://www.globenewswire.com/NewsRoom/AttachmentNg/ff14fff4-666d-4584-853b-f12231260151
Tony (Bizuo) Liu, CEO of the Company, addressed
the audience and media present saying, “We are very pleased to meet
this milestone of expanding our GMP facility space to include this
brand new 100,000-square-foot space with a top-of-the-line GMP
facility. We now have three manufacturing facilities in China
(Beijing, Shanghai, and Wuxi) with a total GMP capacity of 70,000
square feet, which prepares us for scaled-up demand for our current
and future CAR-T clinical studies. The ability to produce all
plasmids and viral vectors in-house with a high yield, automated,
closed cell culture system and integrated
Chemistry, Manufacturing, and Controls (“CMC”) processes,
provides us with a key differentiator in the CAR-T and regenerative
medicine space.”
“In addition to our state-of-the-art facilities,
we are very privileged to partner with leaders in the
biopharmaceutical, digital and manufacturing fields, and look
forward to reaping a mutual benefit from the wealth of data and
shared knowledge. We appreciate the role that every partner,
hospital collaborator, employee, director, advisor and shareholder,
both past and present, has played in making CBMG what it is today,
and bringing us all closer to helping the large patient populations
of China and their families.”
A seminar entitled “Standardization,
Digitalization and Clinical Big Data for the Acceleration of New
Drug Development” was held following the ceremony, with
presentations from Dr. Michael Caligiuri, Chair of CBMG External
Advisory Board and President-Elect 2016-2017 of the American
Association for Cancer Research (AACR), Dr. Alan List, Chair of
CBMG Scientific Advisory Board and President and CEO of Moffitt
Cancer Center, Dr. Maria Fardis, CEO of Iovance Biotherapeutics and
Dr. Thomas Vangsness, Jr., Chief of Sports Medicine at University
of Southern California (USC), GE Healthcare and Thermo Fisher
Scientific.
About Cellular Biomedicine
Group Cellular Biomedicine Group, Inc. (NASDAQ:CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of twelve
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. CBMG
currently has ongoing CAR-T Phase I clinical trials in China;
CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin
Lymphoma (NHL) and CALL-1 for adult Acute Lymphoblastic Leukemia
(ALL), utilizing CBMG’s proprietary and optimized CD19 construct,
as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s
“Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem
Cell) for the treatment of Knee Osteoarthritis (KOA). To learn more
about CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contact: Sarah Kelly
Director of Corporate Communications, CBMG +1 408-973-7884 +86 21
5406 9990 sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024